Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 9/20 | 0.46 |
| ▸ | CA12 | O43570 | 6/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 8/20 | 0.45 |
| ▸ | CA9 | Q16790 | 5/20 | 0.45 |
| ▸ | BCL2 | P10415 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14831226 | 0.84 | USP2 (0.56) | MALT1IDO1CA1CA12CA7 | |
| SCHEMBL1161283 | 0.83 | CA1 (0.50) | MALT1IDO1CA1CA12CA7 | |
| SCHEMBL5394506 | 0.80 | CA1 (0.57) | CA1CA12CA7CA14CA2 | |
| SCHEMBL28056834 | 0.80 | CA1 (0.49) | CA1CA12CA7CA14CA2 | |
| SCHEMBL27464975 | 0.79 | IDO1 (0.46) | MALT1IDO1CA1CA12CA7 | |
| SCHEMBL27202571 | 0.77 | MMP2 (0.53) | MALT1CA1CA12CA7CA14 | |
| SCHEMBL1542090 | 0.77 | L3MBTL1 (0.57) | MALT1IDO1CA1CA12CA7 | |
| SCHEMBL27448413 | 0.76 | CA1 (0.47) | MALT1IDO1CA1CA12CA7 | |
| SCHEMBL21780202 | 0.75 | IDO1 (0.51) | MALT1IDO1CA1CA12CA7 | |
| Toluene SCHEMBL28585498 | 0.75 | CA12 (0.52) | CA1CA12CA7CA14CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3617198-B1 | GUANIDINE DERIVATIVE | LUNAN PHARMACEUTICAL GROUP CORP (CN) | 2023-10-25 | — | — | EP | disclosed |
| US-20200325109-A1 | IMINO-UREA DERIVATIVES | Carolina Cloud Exchange Inc. | 2020-10-15 | — | — | US | disclosed |
| EP-3617198-A1 | GUANIDINE DERIVATIVE | Lunan Pharmaceutical Group Corporation (CN) | 2020-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325109-A1 | IMINO-UREA DERIVATIVES | IDO2, IDO1, INMT | MALT1 1740/4885IDO1 2/4885CA1 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.